I am a molecular geneticist with a special interest in molecular pathology determining the inherited and somatic genetic events that predispose to, and advance cancer development. Much of this work has immediate translatability to clinical genetics practi
Using MiR-200 To Find New Therapeutic Targets For Neuroblastoma
Funder
National Health and Medical Research Council
Funding Amount
$563,152.00
Summary
Neuroblastoma is one of the most common cancers in children. We have found that a genetic regulator, called microRNA, can limit the ability of neuroblastoma cells to invade surrounding tissues and metastasise. We aim use the microRNAs to find new therapeutic targets that may work in combination with existing treatments, reducing the short term toxicity and long term deleterious effects of current treatments.
Risk Of Recurrence After Diagnosis Of Invasive Breast Cancer By Molecular Subtype As Defined By ER, PR And Her2 Status
Funder
National Health and Medical Research Council
Funding Amount
$500,622.00
Summary
Breast cancer is a heterogeneous disease. Molecular subtypes have been identified that differ in terms of prognosis and response to treatment. This study aims to estimate recurrence free survival of breast cancer by molecular subtypes in a population-based sample of Australian women. The results will assist clinicians to guide their therapeutic decisions and will inform women about their anticipated outcome after diagnosis of breast cancer.
Lung cancer is the most frequent cause of cancer deaths in many Western countries, including ours. Lung cancer is the third leading cause of death of Australians and the fifth leading cause of burden of disease in Australia. With exposure to cancer-causing agents such as cigarette smoke, parts of the lung may suffer permanent damage that increases the risk of lung cancer. Many of these changes include the genes in air passages and lung tissue. A certain change (called methylation) affects some g ....Lung cancer is the most frequent cause of cancer deaths in many Western countries, including ours. Lung cancer is the third leading cause of death of Australians and the fifth leading cause of burden of disease in Australia. With exposure to cancer-causing agents such as cigarette smoke, parts of the lung may suffer permanent damage that increases the risk of lung cancer. Many of these changes include the genes in air passages and lung tissue. A certain change (called methylation) affects some genes in the lungs, but it is not yet known how common this change is or how it affects smokers and people who have developed lung cancer. We will collect blood and sputum specimens from lung cancer patients to test to see if methylation is present, and also specimens from when patients have a routine bronchoscopy as part of their initial tests. If they have an operation for lung cancer, then the part of the lung that is removed and not needed for diagnosis will also be tested for methylation. In this study, we will study whether methylation is an accurate test for lung cancer, whether it is present in parts of the lung near from the lung cancer, and whether it predicts better or worse results after treatment. We hope that this research study will provide new information about the diagnosis and treatment of lung cancer.Read moreRead less
Improving Outcomes For Women Diagnosed With Mucinous Ovarian Cancer
Funder
National Health and Medical Research Council
Funding Amount
$598,238.00
Summary
Mucinous ovarian cancer (MOC) is different from other ovarian cancers but few studies have characterized the genetic changes specific to this subtype. It is often confused with metastases from other organs and does not respond well to standard ovarian cancer therapies. If MOC is more similar to mucinous cancers from other organs than other ovarian cancers, it may be better treated with chemotherapeutics that show success with other mucinous tumours.
Aberrant Transcriptional Signalling In The Progression And Metastasis Of Melanoma.
Funder
National Health and Medical Research Council
Funding Amount
$353,033.00
Summary
There are currently no treatments that have any impact on decreasing mortality from metastatic melanoma. We have found 2 new variants in melanoma that may control the tumour growing and invading around the body. This study will examine the protein containing these changes with the aims of finding how they function differently, to identify their roles in the formation of melanoma, as well as to identify new targets for prevention and treatment of metastatic disease.
Deciphering Tumour Heterogeneity Of Breast Cancer Metastases Using Barcoded Patient Derived Xenografts
Funder
National Health and Medical Research Council
Funding Amount
$583,161.00
Summary
Breast cancer mortality is largely due to metastases that seed from the primary tumour. Breast tumours are known to contain a heterogeneous mix of cells, but the precise way that cells are selected for tumour growth and metastasis (as well as their response to systemic therapy) is not well understood. In this study we will use patient samples and cellular ‘barcoding’ to track the destiny of every single clone throughout disease progression and study the effect of various therapies on metastasis.
Regulation Of Innate Immunity And Tumour Progression By Activating Transcription Factor 3
Funder
National Health and Medical Research Council
Funding Amount
$473,469.00
Summary
Toll-like receptors (TLRs) play an essential role in innate immune responses and are involved in initiating tumourigenesis via inflammatory pathways. We have shown that the transcription factor ATF3 is a negative regulator of TLR signalling. We will study how modulation of the activity of ATF3 affects the inflammatory response and tumour progression. This will provide a molecular basis on which to design therapeutic reagents for the treatment of cancer.
In this grant we aim to study the moecular basis of cancer. The promoter regions of tumour suppressor genes are often modified in cancer by a chemical process called methylation. Methylation of DNA is associated with gene silencing. Therefore DNA methylation is commonly regarded as causing the silencing of genes in cancer. In this grant, we aim to determine if methylation is causal in triggering gene silencing in cancer, or if methylation is a consequence of gene silencing. This is a critical di ....In this grant we aim to study the moecular basis of cancer. The promoter regions of tumour suppressor genes are often modified in cancer by a chemical process called methylation. Methylation of DNA is associated with gene silencing. Therefore DNA methylation is commonly regarded as causing the silencing of genes in cancer. In this grant, we aim to determine if methylation is causal in triggering gene silencing in cancer, or if methylation is a consequence of gene silencing. This is a critical distinction in understanding the role of methylation in cancer development.Read moreRead less
Understanding The Development Of Pancreatic Islet Cell Tumours
Funder
National Health and Medical Research Council
Funding Amount
$579,163.00
Summary
We will use mouse models of pancreatic cancer that we have established previously to investigate the molecular basis of the development and progression of tumours in the insulin-producing cells of the pancreas. We propose to manipulate a small number of candidate genes using established islet cultures and new mouse models in order to characterise the effect they have on islet cell biology and tumorigenesis.